Michael A Postow

Michael A Postow

UNVERIFIED PROFILE

Are you Michael A Postow?   Register this Author

Register author
Michael A Postow

Michael A Postow

Publications by authors named "Michael A Postow"

Are you Michael A Postow?   Register this Author

100Publications

8052Reads

22Profile Views

Toxicities of checkpoint inhibitors: causes and management.

Authors:
Michael A Postow

Clin Adv Hematol Oncol 2019 Apr;17(4):220-222

Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
April 2019

Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma.

Clin Cancer Res 2018 10 14;24(20):4915-4917. Epub 2018 Jun 14.

Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-1311DOI Listing
October 2018

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

N Engl J Med 2018 Aug;379(8):722-730

From the University of Texas M.D. Anderson Cancer Center, Houston (H.A.T.); Moffitt Cancer Center and Research Institute, Tampa, FL (P.A.F., N.I.K.); University of California-San Francisco, San Francisco (A. Algazi), the Angeles Clinic and Research Institute, Los Angeles (O.H.), Stanford University Hospital, Palo Alto (R.P.T.), and the Department of Medical Oncology, City of Hope, Duarte (K.M.) - all in California; Dana-Farber Cancer Institute, Boston (F.S.H., D.A.R.); University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill (S.J.M.); University of Colorado Comprehensive Cancer Center, Aurora (K.L.); University of Michigan, Ann Arbor (C.D.L.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (M.A.P.), Roswell Park Cancer Institute, Buffalo (M.S.E., I.P.), and New York University, Lake Success (A.C.P.) - all in New York; Georgetown-Lombardi Comprehensive Cancer Center, Washington DC (M.B.A.); Winship Cancer Institute of Emory University, Atlanta (R.R.K.); University of Pittsburgh Medical Center, Pittsburgh (A.T.); Bristol-Myers Squibb, Princeton, NJ (J.J., A. Avila, S.D.); and Cleveland Clinic-Taussig Cancer Institute, Cleveland (A.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1805453DOI Listing
August 2018

Immune-related Adverse Events in Cancer Patients.

Acad Emerg Med 2018 07 25;25(7):819-827. Epub 2018 May 25.

Clinical Research Division, Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/acem.13443DOI Listing
July 2018

Non-conventional Inhibitory CD4Foxp3PD-1 T Cells as a Biomarker of Immune Checkpoint Blockade Activity.

Cancer Cell 2018 06;33(6):1017-1032.e7

Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medicine, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.05.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6648657PMC
June 2018

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

J Immunother 2017 Nov/Dec;40(9):334-340

*Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA †The University of Texas MD Anderson Cancer Center, Houston, TX ‡Memorial Sloan Kettering Cancer Center §Weill Cornell Medical College §§NYU Clinical Cancer Center, New York, NY ∥The Angeles Clinic and Research Institute, Los Angeles ¶Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco ††The John Wayne Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA #Mayo Clinic, Rochester, MN **Mayo Clinic, Jacksonville, FL ‡‡Dana-Farber Cancer Institute, Boston, MA ∥∥Yale Cancer Center, New Haven, CT ¶¶Clinigen, Weybridge, UK ##Merck & Co. Inc., Kenilworth, NJ ***Duke Cancer Institute, Durham, NC.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00002371-900000000-9951
Publisher Site
http://dx.doi.org/10.1097/CJI.0000000000000186DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647109PMC
May 2018

Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?

Authors:
Michael A Postow

Clin Adv Hematol Oncol 2018 May;16(5):353-355

Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
May 2018

The brim of uncertainty in adjuvant treatment of melanoma.

Lancet Oncol 2018 04 21;19(4):436-437. Epub 2018 Feb 21.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, 300 East 66th Street, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30150-5DOI Listing
April 2018

Reply to M. Horiguchi et al.

J Clin Oncol 2018 03 16;36(7):721. Epub 2018 Jan 16.

Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, Essen, Germany; Joel Jiang and Thomas Kelleher, Bristol-Myers Squibb, Princeton, NJ; and Michael A. Postow, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.5339DOI Listing
March 2018

Adverse Events Associated with Immune Checkpoint Blockade.

N Engl J Med 2018 03;378(12):1165

Memorial Sloan Kettering Cancer Center, New York, NY

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1801663DOI Listing
March 2018

Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research.

Clin Cancer Res 2018 02 23;24(4):730-736. Epub 2017 Aug 23.

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-1355DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963278PMC
February 2018

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.

J Clin Oncol 2018 02 17;36(4):391-398. Epub 2017 Oct 17.

Margaret K. Callahan, Michael A. Postow, Neil H. Segal, Alexander Lesokhin, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY; Harriet Kluger and Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, and Yale-New Haven Hospital, New Haven, CT; Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; John M. Kirkwood, University of Pittsburgh Medical Center, Pittsburgh, PA; and Suba Krishnan, Rafia Bhore, and Christine Horak, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.72.2850
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.72.2850DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946731PMC
February 2018

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.

N Engl J Med 2018 01;378(2):158-168

From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMra1703481DOI Listing
January 2018

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.

J Clin Oncol 2017 Dec 25;35(34):3807-3814. Epub 2017 Aug 25.

Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; Piotr Rutkowski, Maria Skłodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy and Université Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.2289DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791828PMC
December 2017

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2017 10 11;377(14):1345-1356. Epub 2017 Sep 11.

From the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W., M.A.P., M.K.C.); Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua (V.C.-S.), European Institute of Oncology, Milan (P.F.F.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; University of Colorado, Denver (R.G.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Aix-Marseille University, Hôpital de la Timone, Marseille (J.-J.G.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint-Louis, Université Paris Diderot, Paris (C.L.) - both in France; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); University of Michigan, Ann Arbor (C.D.L.); the College of Medicine, Swansea University, Swansea (J.W.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Cross Cancer Institute, Edmonton, AB (M.S.), and Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Universitäts Spital, Zurich, Switzerland (R.D.); Tasman Oncology Research, Southport Gold Coast, QLD (A.H.), Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney (M.S.C.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and Peter MacCallum Cancer Centre (G.M.) and the Olivia Newton-John Cancer Research Institute, University of Melbourne (J.C.), Melbourne, VIC - all in Australia; Netherlands Cancer Institute, Amsterdam (J.H.); University Hospitals Leuven, KU Leuven, Leuven, Belgium (O.B.); General University Hospital Gregorio Marañón, Madrid (I.M.-R.); Northwestern University, Chicago (J.S.); Bristol-Myers Squibb, Princeton, NJ (D.W., L.R., R.B.); and the Dana-Farber Cancer Institute, Boston (F.S.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709684DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706778PMC
October 2017

Treatment of advanced melanoma - A changing landscape.

Rev Assoc Med Bras (1992) 2017 Sep;63(9):814-823

Oncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/1806-9282.63.09.814DOI Listing
September 2017

Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy in Need of Further Investigation.

Cancer J 2017 Jan/Feb;23(1):32-39

From the *Department of Radiation Oncology, †Melanoma and Immunotherapeutics Oncology Service, Department of Medicine, and ‡Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00130404-201701000-000
Publisher Site
http://dx.doi.org/10.1097/PPO.0000000000000236DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300083PMC
August 2017

OncoKB: A Precision Oncology Knowledge Base.

JCO Precis Oncol 2017 Jul 16;2017. Epub 2017 May 16.

, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , , Department of Hematology and Oncology, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Department of R&D and Bioinformatics, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Oncology and Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
https://www.researchgate.net/profile/Debyani_Chakravarty/pub
Web Search
http://ascopubs.org/doi/10.1200/PO.17.00011
Publisher Site
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586540PMC
http://dx.doi.org/10.1200/PO.17.00011DOI Listing
July 2017

Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab.

J Natl Cancer Inst 2017 04 31;109(4). Epub 2016 Dec 31.

Affiliations of authors: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY (CFF, VC, TB, ANS, PM, MKC, JDW, PBC, MDH, MAP); Weill Cornell Medical College, New York, NY (CFF, AVR, ANS, PM, MKC, JDW, PBC, MDH, MAP).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw260DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441295PMC
April 2017

A step forward for patients with NRAS-mutant melanoma.

Lancet Oncol 2017 04 9;18(4):414-415. Epub 2017 Mar 9.

Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30172-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540131PMC
April 2017

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.

EBioMedicine 2017 Apr 24;18:56-61. Epub 2017 Mar 24.

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Weill Cornell Medical College, New York, NY, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2017.03.029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405176PMC
April 2017

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

J Clin Oncol 2017 Mar 30;35(7):709-717. Epub 2016 Sep 30.

Jarushka Naidoo, Kaitlin M. Woo, Tunc Iyriboz, Darragh Halpenny, Jane Cunningham, Jamie E. Chaft, Neil H. Segal, Margaret K. Callahan, Alexander M. Lesokhin, Jonathan Rosenberg, Martin H. Voss, Charles M. Rudin, Hira Rizvi, Xue Hou, Katherine Rodriguez, Melanie Albano, Ruth-Ann Gordon, Charles Leduc, Natasha Rekhtman, Bianca Harris, Jedd D. Wolchok, Michael A. Postow, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Jamie E. Chaft, Neil H. Segal, Margaret K. Callahan, Alexander M. Lesokhin, Jonathan Rosenberg, Martin H. Voss, Charles M. Rudin, Jedd D. Wolchok, Michael A. Postow, and Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Jarushka Naidoo, Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, MD; Xuan Wang, Peking University Cancer Hospital and Institute, Beijing; Xue Hou, Sun Yat-sen University Cancer Center, Guangdong Province, People's Republic of China; Xuan Wang, Matteo S. Carlino, Benjamin Y. Kong, and Georgina V. Long, The University of Sydney; Alexander M. Menzies and Alexander D. Guminski, Royal North Shore and Mater Hospital; and Matteo S. Carlino and Benjamin Y. Kong, Westmead and Blacktown Hospitals, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559901PMC
March 2017

Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.

Melanoma Res 2017 02;27(1):57-64

aMelanoma and Immunotherapeutics Service, Department of Medicine bDepartment of Radiology cDepartment of Epidemiology and Biostatistics dDepartment of Surgery, Memorial Sloan Kettering Cancer Center eWeill Cornell Medical College fColumbia University Medical Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000306DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553194PMC
February 2017

Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment.

J Clin Oncol 2017 01 28;35(2):139-140. Epub 2016 Nov 28.

Jeffrey S. Weber, New York University Langone Medical Center, New York, NY; Laura A. Levit, American Society of Clinical Oncology, Alexandria, VA; Peter C. Adamson, The Children's Hospital of Philadelphia, Philadelphia, PA; Suanna S. Bruinooge, American Society of Clinical Oncology, Alexandria, VA; Howard A. Burris III, Sarah Cannon Research Institute, Nashville, TN; Michael A. Carducci, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Adam P. Dicker, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA; Mithat Gönen, Memorial Sloan Kettering Cancer Center, New York, NY; Stephen M. Keefe, University of Pennsylvania, Philadelphia, PA; Michael A. Postow, Memorial Sloan Kettering Cancer Center, New York, NY; Michael A. Thompson, Aurora Health Care, Milwaukee, WI; David M. Waterhouse, Oncology Hematology Care, Cincinnati, OH; Susan L. Weiner, Children's Cause for Cancer Advocacy, Washington, DC; and Lynn M. Schuchter, University of Pennsylvania, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.4692DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559890PMC
January 2017

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.

JAMA Oncol 2016 Oct;2(10):1346-1353

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York2Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.1051DOI Listing
October 2016

A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.

Melanoma Res 2016 06;26(3):272-7

aMelanoma and Immunotherapeutics Service bMolecular Imaging and Therapy Service cDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center dWeill Cornell Medical College eDivision of Hematology/Oncology, Columbia University Medical Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000234DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553199PMC
June 2016

Irradiation and immunotherapy: From concept to the clinic.

Cancer 2016 Jun 23;122(11):1659-71. Epub 2016 Feb 23.

Department of Radiation Oncology, Duke University, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29889DOI Listing
June 2016

Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.

Immunotherapy 2016 06;8(7):821-37

Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2016-0002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619130PMC
June 2016

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.

Cancer Immunol Res 2016 05 29;4(5):383-9. Epub 2016 Feb 29.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Weill Cornell Medical College, New York, New York. Department of Dermatology, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241697PMC
May 2016

Targeting T Cell Co-receptors for Cancer Therapy.

Immunity 2016 05;44(5):1069-78

Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, Cornell University, New York, NY 10065, USA; Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.immuni.2016.04.023DOI Listing
May 2016

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.

Curr Oncol Rep 2016 Apr;18(4):21

Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063308PMC
http://dx.doi.org/10.1007/s11912-016-0509-xDOI Listing
April 2016

Reply to A. Indini et al.

J Clin Oncol 2016 Mar 19;34(9):1018-9. Epub 2016 Jan 19.

Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.7007DOI Listing
March 2016

Managing immune checkpoint-blocking antibody side effects.

Authors:
Michael A Postow

Am Soc Clin Oncol Educ Book 2015 :76-83

From the Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.76DOI Listing
February 2016

Checkpoint Blockade for the Treatment of Advanced Melanoma.

Cancer Treat Res 2016 ;167:231-50

Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-22539-5_9DOI Listing
January 2016

Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement.

J Clin Oncol 2015 Nov 20;33(32):3826-33. Epub 2015 Jul 20.

Arti Hurria, City of Hope, Duarte; Louis Fehrenbacher, Kaiser Permanente Northern California, Vallejo, CA; Enrique Soto-Perez-de-Celis, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; Laura A. Levit and Suanna S. Bruinooge, American Society of Clinical Oncology, Alexandria, VA; William Dale, University of Chicago Medical Center, Chicago, IL; Supriya G. Mohile and Allison Magnuson, University of Rochester Medical Center, Rochester; Stuart M. Lichtman, William P. Tew, and Michael A. Postow, Memorial Sloan Kettering Cancer Center, New York, NY; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill; and Harvey J. Cohen, Duke University Medical Center, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.0319DOI Listing
November 2015

Targeting immune checkpoints in melanoma: an update.

Melanoma Manag 2015 Nov 24;2(4):339-352. Epub 2015 Nov 24.

Melanoma & Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/mmt.15.25
Publisher Site
http://dx.doi.org/10.2217/mmt.15.25DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094685PMC
November 2015

Safety of Infusing Ipilimumab Over 30 Minutes.

J Clin Oncol 2015 Oct 29;33(30):3454-8. Epub 2015 Jun 29.

Parisa Momtaz, Vivian Park, Katherine S. Panageas, Michael A. Postow, Margaret Callahan, Jedd D. Wolchok, and Paul B. Chapman, Memorial Sloan-Kettering Cancer Center; Jedd D. Wolchok, Ludwig Institute for Cancer Research; and Michael A. Postow, Margaret Callahan, Jedd D. Wolchok, and Paul B. Chapman, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.0030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087314PMC
October 2015

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.

J Clin Oncol 2015 Oct 17;33(28):3193-8. Epub 2015 Aug 17.

Troy Z. Horvat, Nelly G. Adel, Thu-Oanh Dang, Kaitlin M. Woo, Katherine S. Panageas, Parisa Momtaz, Michael A. Postow, Margaret K. Callahan, Richard D. Carvajal, Mark A. Dickson, Sandra P. D'Angelo, Jedd D. Wolchok, and Paul B. Chapman, Memorial Sloan Kettering Cancer Center; Jedd D. Wolchok, Ludwig Institute for Cancer Research; and Michael A. Postow, Margaret K. Callahan, Richard D. Carvajal, Mark A. Dickson, Sandra P. D'Angelo, Jedd D. Wolchok, and Paul B. Chapman, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.60.8448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087335PMC
October 2015

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

N Engl J Med 2015 Jul 31;373(1):23-34. Epub 2015 May 31.

From the Department of Medical Oncology, Royal Marsden Hospital, London (J.L.), and South West Wales Cancer Institute, Singleton Hospital, Swansea (J.W.) - both in the United Kingdom; Melanoma Oncology Unit, Veneto Region Oncology Research Institute, Padua (V.C.-S.), Oncology of Melanoma Unit, European Institute of Oncology, Milan (P.F.F.), University Hospital of Siena, Siena (M.M.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; Division of Medical Oncology, University of Colorado, Denver, Denver (R.G.); Aix-Marseille University, Hôpital de La Timone, Assitance Publique-Hôpitaux de Marseille, Marseille (J.J.G.), and Hôtel Dieu Place Alexis Ricordeau, Nantes (B.D.) - both in France; Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); Departments of Internal Medicine and Dermatology, University of Michigan, Ann Arbor (C.D.L.); Department of Dermatology, University of Essen, Essen, Germany (D.S.); University of Zürich Hospital, Zurich, Switzerland (R.D.); Cross Cancer Institute, Edmonton, AB, Canada (M. Smylie); Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland (P.R.); Tasman Oncology Research, Southport Gold Coast, QLD (A.H.), and Westmead and Blacktown Hospitals (M.S.C.) and Melanoma Institute Australia (M.S.C., G.V.L.), University of Sydney, and the Mater Hospital (G.V.L.), Sydney, and Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC (G.A.M.) - all in Australia; Division of Medical Oncology, the Netherlands Cancer Institute, Amsterdam (J.B.H.); Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid (I.M.-R.); Ludwig Center, Memorial Sloan Kettering Cancer Center (M.K.C., M.A.P., J.D.W.) and Weill Cornell Medical College (M.K.C., M.A.P., J.D.W.) - both in New York; Huntsman Cancer Institute, University of Utah, Salt Lake City (K.G.); Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital, Yale University Sc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1504030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698905PMC
July 2015

Immune checkpoint modulation: rational design of combination strategies.

Pharmacol Ther 2015 Jun 10;150:23-32. Epub 2015 Jan 10.

Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College Cornell University, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01637258150000
Publisher Site
http://dx.doi.org/10.1016/j.pharmthera.2015.01.003DOI Listing
June 2015

Immune Checkpoint Blockade in Cancer Therapy.

J Clin Oncol 2015 Jun 20;33(17):1974-82. Epub 2015 Jan 20.

All authors: Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.4358DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980573PMC
June 2015

Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.

Int J Radiat Oncol Biol Phys 2015 Jun 5;92(2):368-75. Epub 2015 Mar 5.

Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2015.01.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955924PMC
June 2015

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma.

J Immunother Cancer 2015 16;3:23. Epub 2015 Jun 16.

Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA ; Weill Cornell Medical College, 525 E 68th Street, New York, 10065 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-015-0070-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469400PMC
June 2015

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

N Engl J Med 2015 May 20;372(21):2006-17. Epub 2015 Apr 20.

From Memorial Sloan Kettering Cancer Center (M.A.P., J.D.W.), Weill Cornell Medical College (M.A.P., J.D.W.), and New York University, Perlmutter Cancer Center (A.C.P.) - all in New York; J. Graham Brown Cancer Center, University of Louisville, Louisville, KY (J.C.); Institute Gustave Roussy, Villejuif (C.R.), Paris-Sud University, Orsay (C.R.), and Institut Universitaire du Cancer, Toulouse (N.M.) - all in France; Huntsman Cancer Institute, Salt Lake City (K.G.); Beth Israel Deaconess Medical Center (D. McDermott) and Dana-Farber Cancer Institute (P.A.O., F.S.H.) - both in Boston; Washington University in St. Louis, St. Louis (G.P.L.); Greenville Health System, Greenville, SC (J.K.G.); St. Luke's Cancer Center, Bethlehem, PA (S.S.A.); University of New Mexico, Albuquerque (M.S.); Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (M.S.E.); California Pacific Center for Melanoma Research, San Francisco (D. Minor); Duke University, Durham, NC (A.K.S.); Oregon Health and Science University, Portland (M.T.); Bristol-Myers Squibb, Lawrenceville, NJ (C.H.); and Bristol-Myers Squibb, Wallingford, CT (L.M.R., P.G.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1414428DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744258PMC
May 2015

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.

Sci Transl Med 2015 Mar;7(280):280sr1

Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3010274DOI Listing
March 2015

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic.

Front Oncol 2014 15;4:385. Epub 2015 Jan 15.

Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center , New York, NY , USA ; Weill Cornell Medical College , New York, NY , USA ; Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center , New York, NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2014.00385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295550PMC
February 2015

American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.

J Clin Oncol 2015 Jan 15;33(3):278-84. Epub 2014 Dec 15.

Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa, FL; Laura A. Levit and Suanna Bruinooge, American Society of Clinical Oncology, Alexandria, VA; Peter C. Adamson, Children's Hospital of Philadelphia; Adam P. Dicker, Jefferson Medical College, Thomas Jefferson University; Stephen M. Keefe and Lynn M. Schuchter, University of Pennsylvania, Philadelphia, PA; Howard A. Burris IIII, Sarah Cannon Research Institute, Nashville, TN; Michael A. Carducci, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD; Mithat Gönen and Michael A. Postow, Memorial Sloan-Kettering Cancer Center, New York, NY; Michael A. Thompson, Aurora Health Care, Milwaukee, WI; David M. Waterhouse, Oncology Hematology Care, Cincinnati, OH; and Susan L. Weiner, Children's Cause for Cancer Advocacy, Washington, DC.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/3/278.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.2635
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.2635DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516884PMC
January 2015

Genetic basis for clinical response to CTLA-4 blockade in melanoma.

N Engl J Med 2014 Dec 19;371(23):2189-2199. Epub 2014 Nov 19.

Department of Medicine (A.S., T.M., M.A.P., J.D.W.), Human Oncology and Pathogenesis Program (A.S., V.M., A.D., L.A.W., K.K., T.A.C.), Swim across America-Ludwig Collaborative Research Laboratory (T.M., Y.L., C.E., C.L., J.D.W.), Department of Radiation Oncology (T.A.C.), Department of Pathology (T.J.H.), and Immunology Program, Ludwig Center for Cancer Immunotherapy (J.Y., P.W., T.S.H., J.D.W.), Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College (A.S., M.A.P., J.D.W., T.A.C.); and Department of Mathematics, Columbia University (C.B.) - all in New York; the Department of Molecular and Medical Pharmacology (J.M.Z., A.R.) and the Department of Medicine, Division of Hematology-Oncology, Jonsson Comprehensive Cancer Center (A.R.), University of California, Los Angeles, Los Angeles; and Bristol-Myers Squibb, Princeton, NJ (C.T.H., L.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1406498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315319PMC
December 2014

Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway.

Pharmgenomics Pers Med 2014 15;7:357-65. Epub 2014 Nov 15.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA ; Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/PGPM.S53163DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238865PMC
December 2014

CTLA-4 antibodies: new directions, new combinations.

Oncology (Williston Park) 2014 Nov;28 Suppl 3:6-14

View Article

Download full-text PDF

Source
November 2014

Ipilimumab in patients with melanoma and autoimmune disease.

J Immunother Cancer 2014 14;2(1):35. Epub 2014 Oct 14.

Melanoma and Immunotherapeutics Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065 USA ; Weill Cornell Medical College, 525 E 68th Street, New York, NY 10065 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-014-0035-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207313PMC
October 2014

Opportunistic infections in patients treated with immunotherapy for cancer.

J Immunother Cancer 2014 18;2:19. Epub 2014 Jun 18.

Memorial Sloan-Kettering Cancer Center, Melanoma and Immunotherapeutics Oncology Service, 300 East 66th Street, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://jitc.biomedcentral.com/articles/10.1186/2051-1426-2-1
Publisher Site
http://dx.doi.org/10.1186/2051-1426-2-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079190PMC
July 2014